AtaiBeckley (NASDAQ:ATAI) shares jumped as much as 53% in premarket trading on Thursday after reports emerged that Eli Lilly (NYSE:LLY) is in discussions to acquire the psychedelic drug developer.
According to BMO Capital Markets analyst Evan David Seigerman, an acquisition of AtaiBeckley would strengthen Eli Lilly’s presence in psychiatry while supporting its strategy of expanding beyond its established cardiometabolic business.
“While Lilly has significantly increased its commercial development activity across several therapeutic areas, AtaiBeckley would provide differentiated exposure to psychiatry and strengthen the company’s broader commitment to diversifying beyond its core cardiometabolic franchise,” Seigerman said.
Seigerman noted that the proposed transaction could provide Eli Lilly with a differentiated late-stage neuropsychiatric programme, while also expanding its broader development pipeline.
The analyst highlighted VLS-01, which is being developed for treatment-resistant depression, and EMP-01, a potential therapy for social anxiety disorder, as additional assets that could enhance Lilly’s long-term neuroscience portfolio if a deal is completed.
The companies have not publicly confirmed any agreement, and discussions remain subject to the outcome of ongoing negotiations.
Eli Lilly stock price
AtaiBeckley stock price
| Nov-14 | |
| Nov-14 | |
| Nov-13 | |
| Nov-12 | |
| Nov-12 | |
| Nov-12 | |
| Nov-12 | |
| Nov-12 | |
| Nov-12 | |
| Nov-12 |
Beyond GLP-1RAs: Novel mechanisms and combos to shape future of obesity market
LLY
Pharmaceutical Technology
|
| Nov-12 | |
| Nov-12 | |
| Nov-12 | |
| Nov-12 | |
| Nov-12 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite